Key Takeaway: RenovoRx announced positive interim results from the Phase 3 TIGeR-PaC study, focusing on the use of RenovoGem for treating locally advanced pancreatic cancer. The findings, which indicate improved progression-free survival, were presented at the 2023 ESMO World Congress. Dr. Michael Pishvaian from Johns Hopkins Medicine led the presentation.
Price reaction · baseline $1.95 (2023-07-28 close) · clean, no other RNXT news in the window
day 0 close · peak
+1.5%
Market Sentiment Analysis
POSITIVE FACTORS
Positive interim data on progression-free survival reported.
RenovoGem shows promise for patients with locally advanced pancreatic cancer.
Presentation at a prestigious conference highlights the significance of findings.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer
Full Press Release Details
RenovoRx (NASDAQ:RNXT) presented new positive data on progression-free survival from the pivotal Phase 3 open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer.
The interim data was featured as a late-breaking oral presentation at the 2023 ESMO World Congress on Gastrointestinal Cancer, and presented by Michael Pishvaian, M.D., Ph.D., Johns Hopkins Medicine and principal Investigator of the TIGeR-PaC study.
View the entire article on Bio Tuesdays
Frequently Asked Questions
What is the TIGeR-PaC study?
The TIGeR-PaC study is a pivotal Phase 3 trial evaluating RenovoGem in pancreatic cancer.
What were the results of the Phase 3 study?
The interim results showed positive data on progression-free survival for patients.
Where was the data presented?
The data was presented at the 2023 ESMO World Congress on Gastrointestinal Cancer.
Who presented the interim data?
Dr. Michael Pishvaian from Johns Hopkins Medicine presented the data.